Formation of core-shell nanocomposites of Fenofibrate and Itraconazole, model poorly water soluble drugs, via fluidized bed (FB) coating of their well-stabilized high drug 15 loaded nanosuspensions is investigated. Specifically, the extent of dissolution enhancement, when fine carrier particles (sub-50m) as opposed to the traditional large carrier particles (>300µm) are used, is examined. This allowstestingthe hypothesis that greatly increased carrier surface area andmore importantly, thinner shell for finer carriers at the same drug loading can significantly increase the dissolution ratewhen spray-coated 20 nanosuspensions are well-stabilized. Fine sub-50 µm lactose (GranuLac This is attributed to a much higher specific surface area of the carrier andcorresponding thinner coating layer for fine carriers asopposed to thosefor large carrier particles.
Introduction
The bioavailability of a large percentage (between 40% and 70%) of newly discovered drug compoundis limited by their poor water solubility and slow dissolution rate (Kesisoglou et al., 2007; Lindenberg et al., 2004) .Size reduction of drug crystals to 40 nano-scale increases the specific surface area tremendously, which can increase the dissolution rate of drugs according to the Noyes-Whitney equation (Noyes and Whitney, 1897) . Therefore, preparing a drug nanosuspension via wet media milling andsubsequently converting it into various composite particles and/or nanoparticle agglomerates via spray drying (Azad et al., 2015a; Malamatari et al., 2015; Malamatari et 45 al., 2016) and core-shell nanocomposite microparticles (NCMPs) via fluidized bed coating onto inert excipient particles (Basa et al., 2008; Bhakay et al., 2014a; Bhakay et al., 2014b; Malamatari et al., 2016) have become popular for preparation of oral solid oral dosages and inhalable dry powders.
Wet stirred media milling (WSMM) is an organic solvent-free process and has 50 several distinct advantages such as tunable and relatively high drug concentration, low excipient side effects, ability to run continuously, scalable, etc., and can be universally formulated for most drug candidates with poor water solubility (Li et al., 2016; Malamatari et al., 2015; Merisko-Liversidge et al., 2003; Monteiro et al., 2013) . During the WSMM process, drug suspension along with hard grinding beads is stirred at high 55 speed and subjected to turbulent motion-high shear inside a chamber, which in turn leads to breakage of drug particles captured between the colliding beads (Afolabi et al., 2014) .While WSMM can form a drug nanosuspension with a median size below 1000 nm, nanoparticles can increase in size due to agglomeration and ripening during the milling and storage (Knieke et al., 2013) . Important benefits such as the high surface area can be 60 lost if the nanoparticles grow and/or form large clusters. Hence, it is of great importance to ensure suspension stability not only during the media milling, but also during the subsequent storage. In general, stabilization can be achieved either by electrostatic, steric or electrosteric interactions (Kim, 2004; Napper, 1970) with the use of various stabilizers (refer to the review by Li et al., 2016) including polymers such as hydroxypropyl 65 cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone,etc.; surfactants such as sodium dodecyl sulfate, poloxamer 188/407, d-alpha tocopheryl polyethylene glycol 1000 succinate, Polysorbate 20 and 80, etc.; andnovel class of stabilizers like colloidal particles of superdisintegrants such as sodium starch glycolate and croscarmellose sodium (Azad et al., 2015b) .Optimal concentration of the stabilizers is usually 70 determined by assessing the particle size after wet media milling and during storage at various concentrations of the stabilizers (Knieke et al., 2013) .
For thecore-shell type NCMPs prepared via fluidized bed coating/drying of precursor drug nanosuspensions onto carrier particles, besides the drug particle size, the type-solubility-concentration of the polymerin the shell as well as the thickness of the 75 coating layer and carrier size can impact the drug release rate. The typical fluidized bed coating processes utilize carrier particles as large as 850 m resulting in much larger final nanocomposites (Möschwitzer and Müller, 2006) . In contrast, smaller carrier particles (<50 m) can provide a higher specific surface area for coating, thus potential for achieving fine NCMPs (sub-100 m) (Knieke et al., 2015) . Advantages of the fine 80 nanocomposites include higher drug loadings in the final dosage, excellent content uniformity, minimum segregation tendency, controlled cohesion and good bulk density for speedy downstream processing (e.g. capsule filling or tableting). Moreover, they are preferred for orally disintegrating dosage forms to minimize the sensation of a gritty mouth feel, and can also be used for controlled release of the drug through manipulation 85 of the coating polymer(s). The challenge associated with fine carrier particles is that these carrier particles cannot be fluidized inherently due to their small particle size. Based on empirical observations of fluidization behavior, Geldart (1973) classified powders into four groups (A, B, C, and D) according to their size and the density difference between the particles and the fluidizing medium.Powders with fine particle sizes usuallybelong to 90 group C, whichare inherently un-fluidizable, and exhibit extremely erratic, poor fluidization even if they can be fluidized at all.Dry-coating with nanosized silica prior to the fluidized bed coating greatly reduces the particle cohesion, and henceshifts the powder fluidizabilityof the carrier from Geldart group C (cohesive) to Geldart group A (aeratable) (Chen et al., 2008; Yang et al., 2005) . The purpose of silica coating is strictly 95 to enhance fluidization and the silica gets covered after spray-coating with drug suspensions, hence has no subsequent role in dissolution performance.
Recent investigations show that if the milled suspensions are properly stabilized, core-shell NCMPs having water-soluble core prepared via fluidized bed coating of such stable suspensions can allow for fast dissolution rate for poorly water soluble drugs 100 (Bhakay et al., 2014a; Bhakay et al., 2014b; Möschwitzer and Müller, 2006) .Apart from direct assessment of dissolution behavior, the recovery of drug nanoparticles after redispersion from NCMPs has also been shown to be an important criteria to assess the overall performance of the NCMPs Bhakay et al., 2014b; Bhakay et al., 2013) . Doing so allows for evaluating if the nanoparticles form agglomerates or if 105 they exist in easily dispersible form. These investigations have then shown that both the stability of the milled suspensions and the redispersibility of the dried NCMPs are very important factors.However, the impact of the size of the carrier particle has not been investigated. In this paper, that is the main topic of investigation. Itis hypothesized that finer carriers could further enhance dissolution rate for highly water insoluble drugs 110 because of larger composite particle specific surface area and more importantly,corresponding thinner shells for the same drug loadingas long as the drug particles are nano-sized and suspensions are well-stabilized. In this paper, besides studying the impact of milled drug particle size as modulated by stabilizers, this hypothesisis examined by considering Fenofibrate and Itraconazole as model poorly 115 soluble drugs; noting that the latter is more poorly water soluble and more hydrophobic.
Thisstudydeals specifically with the preparation of NCMPs of twopoorly water soluble BCS Class II drugs,Itraconazole and Fenofibrate.Highly concentrated(30% w/v)drug suspensions were prepared via WSMM.The combined use of a polymer and an anionicsurfactant at various concentrations enabled us to elucidate the impact of drug 120 particle size and stability of the suspensions.Using a fluidized bed coater, these precursor suspensions having three different polymer loadings (1.25, 2.5, and 5%)were coated onto fine sub-50 micron lactose (GranuLac ® 200) to produce fine NCMPs. Fluidization of fine carriers was made possible through dry coating based particle surface modification with hydrophilic nano-silica (M-5P) via reduction of cohesion. To compare with fine carriers, 125 large carrier particles of median size >300 micron (PrismaLac ® 40) were also coated.PrismaLac ® 40 particles are easily fluidized. Therefore, they were used as received without dry coating, which was not necessary.The milled drug particle size and morphologywere characterized via laser diffraction and scanning electron microscopy (SEM). In addition to the stability of the milled suspensions, examination of the recovery 130 of drug nanoparticles after redispersion from NCMPs Bhakay et al., 2014b; Bhakay et al., 2013) helped elucidate the impact of polymer loading and presence of surfactant. The extent of dissolution enhancement for fine carrier particles (sub-50m) as opposed to the traditional large carrier particles (>300µm) was examined for both drugs to test the main hypothesis. 135
Materials and Methods

Materials
Itraconazole (ITZ, antifungal agent) and Fenofibrate (FNB, lipid lowering agent) were purchased from Jai Radhe Sales (Ahmedabad, India). ITZand FNBwere specifically 140 chosen here as modeldrugs owing to their low water solubility (0.1 and 0.8 mg/L, respectively) and relatively hydrophobic nature (Log P: 7.13 and 4.75, respectively Cabot Corporation (GA, USA)and used to dry-coat the fine carriers.
Preparation of DrugSuspensions 155
A schematic of the process used in the preparation of the drug suspensions and nanocompositepowder (NCMPs) is given in Fig. 1 . w/v) were prepared by dissolving the desired amount of stabilizer(s) in 200 ml de-ionized water followed by addition of the drug powder as mixing continued.In this paper, unless otherwise specified, the drug and stabilizer concentrations are weight concentrations with 160 respect to water. Drug nanosuspensions were produced via wet stirred media milling (MicroCer, Netzsch, Exton, PA). The details of mill and milling conditions used in this study can be found in (Knieke et al., 2013; Knieke et al., 2015) . Samples were taken from the outlet ofthe milling chamber for particle sizing.The suspensions were stored under refrigerated conditions (at 8 C) for 7 days to check the storage stability. 165
Preparation of Drug Nanocomposite Powders via Fluidized Bed Coating
The milled drug suspensions (120 g) prepared with0.2 % SDS (H formulations)were sprayed within the same day or the day after milling onto 150 g dry-coated fine Table 2 ) and large as-received carrier 170 particles (PrismaLac powder continued to fluidize and dry for additional 10 min after all the suspension was sprayed. The coated powders were tested for drug assay, particle size, and morphology and were subsequently used in the redispersion and dissolution tests.
Characterization of the Suspensions and Nanocomposite Powders 190
Particle size distributions (PSDs)of the drug suspensions after150 min millingand after 7 days storage were measured with the laser diffraction device LS 13 320 (Coulter Beckman, Miami, FL). A sample of ~1 mL suspension taken from the exit of the milling chamber was dispersed in 5 mL of the stabilizer solution corresponding to the formulation being milled using a vortex mixer (Fisher Scientific Digital vortex mixer, 195 Model No: 945415, USA), which rotated at 1500 rpm for 1 min. ThePSD was determined using the Mie theory at polarization intensity differential scattering (PIDS) of 40%with a dispersant refractive index of 1.33 and the drug particle refractive index of 1.64 and1.546for ITZ and FNB, respectively.
Dry powders (as-received, dry coated, and drug nanocomposites) were analyzed 200 by a Rodos/Helos laser diffraction system (Sympatec, NJ, USA). Approximately 1 g of a powder sample was placed on the sample chute of the Rodos dispersing system and the particle size was measured at a dispersion pressure of 0.5 bar for theas-received and dry coated powders and 0.1 bar for the NCMPs. In order to quantify the degree of agglomeration of the carrier particles that occurred during the fluidized bed coating, the 205 so-called agglomeration ratiowas calculated from the size distributions of coated and uncoated particles (see (Chen et al., 2009a; Knieke et al., 2015) Micron Ltd., UK) (see (Knieke et al., 2015) for details).
The morphology of the drug nanoparticles and theNCMPs, cross-section of the NCMPs, and NCMPs after the redispersion testing was observed via scanning electron microscopy LEO 1530 SVMP (CarlZeiss, Inc., Peabody, MA, USA). A carbon tape was placed on SEM stub, the NCMPs were then placed on the carbon tape and SEM images 215 were taken. For the suspension or sample from the redispersion test,a silicon chip was placed on top of the carbon tape and a drop of thesample was placed on the silicon chip.
For M4H and M5Hsuspensions, a drop of the suspension was first diluted in 10 mL of DI water. The dilution reduced the particle concentration to minimize charging. Thestub with the liquid sample was put in a desiccator and allowed todry overnight under 220 vacuum.All samples were then coated with carbon using BAL-TEC MED 020 (BAL-TEC AG, Balzers, Switzerland) to reduce possible charging effects during the imaging followed by SEM imaging.
To determine the drug content,ITZ composites (100 mg) (F1F3, L1) and FNB composites (300 mg) (F4F6, L2) were dispersed in dichloromethane (10 ml) and 225 acetone (8 ml), respectively followed bysonication for 20 min.After sonication, they were allowed to settle, and an aliquot was taken from the clear supernatant. For ITZ composites, 0.1 ml aliquot was diluted by 5 ml dichloromethane. For FNB composites, 1 ml aliquot was diluted by 8 ml acetone. The diluted aliquots were further sonicated for 2 min to ensure homogeneous mixing and used for Ultraviolet (UV) measurement. The 230 absorbance of ITZ and FNBcompositeswas measured at a wave-length of 260 and 350nm, respectively, by UV Spectrophotometer (Evolution 60S, Thermo Fisher Scientific, USA).
The absorbance was then converted into the drug concentration via established calibration curves of absorbance versus concentration having linear range for ITZ: 0.002-0.10 mg/ml and FNB: 0.06-1.5 mg/ml. Four replicates from each run were used to find 235 the mean drug content in the composites. This information along with the relative standard deviation (RSD) is presented in Table 2 .
Dissolution, UV imaging, and Redispersion of the NCMPs
A dissolution study was carried out using USP II apparatus (paddle method, Distek ® 240 2100, North Brunswick, NJ, USA). NCMPs containing the equivalent of 48 mg of drug (ITZ, FNB) were placed into 900 mL of 25 mM (7.2 mg/ml) SDS at 37 ± 0.5°C and stirred at 50 rpm. To obtain a better differentiation for FNB composites (F4F6), additional dissolution testing was done using 10 mM (2.88 mg/ml) SDS solution. At 1, 2, 5, 10, 20, 30 and 60 min time points, 4 mL of sample was drawn manually and filtered 245 using a PVDF membrane type syringe filter with a nominal pore opening size of 0.1 µm (see for example, (Cerdeira et al., 2010; Juenemann et al., 2011) ). The amount of ITZ andFNB dissolved were measured by UV at wavelengths of 260 and 290 nm, respectively.The respective SDS solution was used as the baseline background for UV measurements. The mean value and standard deviation of three replicates at each 250 dissolution time point were reported.
UV imaging wasperformed forITZ composites (F3 and L1) using an Actipix SDI300 dissolution imaging system (Paraytec Ltd, York, UK). Compacts were made by weighing 6-8 mg of NCMPs (F3, L1) into a stainless steel cylinder (inner diameter: 2 mm) held in a manual press (Actipress, Paraytec Ltd.). A Quickset MINOR torque 255 screwdriver (Torqueleader, M. H. H. Engineering Co. Ltd., UK) was used to compress the composite samples at a constant torque of 20 cNm for 30 s. The compacts were used for the UV imaging during the drug dissolution. The syringe pump (model: Fusion 200, Chemyx Inc., USA) was used for infusion of dissolution medium (7.2 mg/mL SDS) through the quartz channel-flow cell and standard solutions for construction of calibration 260 curves. The flow rate of dissolution medium was at 0.2 mL/min. The selected imaging area was 9 ×7 mm 2 and the pixels (7 × 7 µm 2 ) were binned horizontally in sets of 10 (10×1 pixel binning). UV imaging was performed at 253.7 nm (light path 4.0 mm).
Images were recorded with 2.8 frames per s and analyzed using Actipix D100 software version 1.8 (Paraytec). Pixel intensity was converted into absorbance using the Actipix 265 software, which allows the concentration of the drug substances to be determined as a function of position and time by the use of calibration curves. All experiments were carried out at a temperature of 37±0.5C and in triplicate. The intrinsic dissolution rate (IDR) at one minute intervals was calculated using the software. The software calculates IDR from the absorbance values at each pixel row within the quantification region 270 located downstream from the dissolving sample surface combined with the corresponding flow rate profile (defined by the software), the surface area of the drug compact, the molar mass and the molar absorptivity of ITZ (determined from calibration curves). The calculated dissolution rates were subsequently used by the software to compute the cumulative amount of drug dissolved (Boetker et al., 2011; Gordon et al., 2013) . 275
In order to evaluate the redispersibility of the NCMPs,particle size measurements were carried out after a distinct redispersion procedurementionedbelow and the PSD was comparedwith that of the initial nanosuspensionsimilar to (Bhakay et al., 2014a) .About 1 g of the NCMPs was weighed and dispersed in 30 mL 7.2 (F1F3, L1) or 2.88 mg/mL SDS (F4F6, L2)in a 40 mL beaker and stirred with a laboratory stirrer (CAT R18, 280
Scientific Instrument Center Limited, Winchester, UK) at a speed of 110 rpm for 2 min.Samples were agitated for 2 min to determine if the drug particles are released from the NCMPs fast.Approximately 0.5 ml aliquot of this suspension was taken while stirring and was added to the sample cell of Beckmann Coulter LS13320 for size measurement.
The redispersion media and SDS concentration was kept the same as dissolution media to 285 mimic redispersibility of NCMPs during dissolution.However, to minimize drug dissolution effect and for the sake of stringent discrimination of the potential for full nanoparticle size recovery, small volume of redispersion media (30 mL) and sampling at
Results and Discussion 290
Physical Stabilityof the Drug Suspensions
Highly concentrated(30%) suspensions ofBCS Class II drugs Itraconazoleand Fenofibrate (FNB) were prepared via WSMM using HPMC-SDS combination as the stabilizer system. The desired amount of HPMC (1.25, 2.5, and 5%) and SDS (0.05 and 0.2%) were added initially (see Table 1 ). A low amount of SDS (0.05%) was used before 295 milling to minimize foaming-clogging and ensure proper wetting during milling in all milling experiments. The maximum SDS concentration used was 0.2% (H formulations in Table 1 ), which is below the critical micelle concentration (CMC) of 0.23%, because higher SDS concentration could have significant deleterious effects. Richetti and Kekicheff (Richetti and Kekicheff, 1992) found that the presence of charged micelles 300 could facilitate agglomeration of particles in a suspension. Moreover, with increasing SDS concentration above the CMC, the water-solubility of drug increases significantly (Ghosh et al., 2011; Jamzad and Fassihi, 2006) , which could facilitate Ostwald ripening (Ghosh et al., 2011) . andthe impact of the HPMC concentration at 0.05% and 0.2% SDS.In general, Table 1 shows that for ITZ and FNB an increase in HPMC concentration reduced the extent of aggregation and enhanced the suspension stability (M1−M6). As the primaryparticles become finer and finer during milling, the surfacearea and the number concentration of the particles increaseleading to an increase in the collision frequency and a decreasein 310 inter-particle distances. These changes upon further millingcan cause an increase in the agglomeration rate if the particlesare not protected properly against agglomeration (Bilgili et al., 2004; Sommer et al., 2006) . This was indeed the casewith 1.25 or 2.5% HPMC concentrations as the newly created surfaceswere not adequately covered by the relatively small amount of HPMC along with smaller amount of SDS. The SEM 315 images (Figs. 2a, b, c, g ) showed primary particles with sizesin the range of 50-200 nm.
However, particle size distribution after milling (Table 1) ,as measured via laser diffraction, indicated larger particles, whichconfirms insufficient suspension stability and associated agglomeration of the ITZ or FNB particles due to turbulent shear and Brownian motion during the milling. Higher HPMC concentrations, in particular at level of 5%, help to 320 reduce the particle size drastically by allowing the de-agglomeration of the agglomerates and stabilization of the newly formed particles to a certain extent.HPMC reduces agglomeration through steric stabilization. The HPMC adsorption on FNB nanoparticles follows Langmuir isotherm, which describes the enhanced steric stabilization at higher HPMC concentration (Knieke et al., 2013) . 1.25 and 2.5% HPMC did not lead to 325 complete surface coverage of the drug nanoparticles, and could not effectively prevent agglomeration through steric mechanism, whereas 5% HPMC provides almost full surface coverage according to the Langmuir isotherm.This is also confirmed from primary particle size in SEM images (Figs.2e, f) . Additionally, the particles might have been protected against agglomeration more effectively due to a synergistic stabilization 330 action of the HPMC-SDS combination although as discussed next, higher SDS amounts help further.
The stability condition is further improved with the increase of SDS concentration.A comparison between the milling results with 0.05 and 0.2% surfactant at the same polymer concentration shows decrease of particle size as presented in Table 1 .In 335 fact, for FNB, 2.5% HPMC may be sufficient but as will be seen later from redispersion results, higher HPMC even with 0.2 % SDS is necessary. Overall, in the low submicron range, where the milling response is mainly governed by the quality of stabilization, an increase of SDS concentration (yet smaller than the CMC) facilitates a considerable reduction in particle size. This can be partly explained by enhanced wetting of the 340 particles in the presence of SDS: more effective and faster deagglomeration took place because the stabilizer solution with SDS can penetrate into the small pores of the agglomerates and wet both the primary particles and the agglomerates faster (Kissa, 1999) .
The SEM images (Figs.2d, f, h) confirm the particle size obtained in Table 1 . The particle sizes of the suspension after storage for 7 days exhibited size increase during the storage 345 for ITZ with 1.25 and 2.5 % HPMC even having 0.2% SDS (see Table 1 ). It is noted that the 7 day stability was found to be rather poor and hence was not quantified for suspensions with 0.05% SDS. This increase in size during 7-day storage could be attributed to Brownian agglomeration of the particles caused by insufficient stabilization.
It appears that 5%HPMC-0.2%SDS (M3H) and 2.5% HPMC-0.2% SDS (M5H) 350 combination in the formulation was sufficient to fully stabilize the ITZ and FNB suspensions, respectively during the milling and storage.
Core-Shell Type NCMPs Production via Fluidized Bed Coating
Drug carrying NCMPs were prepared in a fluidized bed coater via spraying of drug 355 suspensions onto carriers, GranuLac Table 2 presents the agglomeration ratio, nanocompositepowder size, the mean drug assay, and flow 360 properties (bulkdensity, angle of repose, and FFC). The drug content of the composites ranged from 12% to 16%, with most composites having a relative standard deviation (RSD) <6%, which is satisfactory as per the United States Pharmacopoeia standards. The FFC of the majority of the composite powderswas >10, which indicates that the composite powdersare free flowing. For ITZ composites,higher polymer loading led to 365 improved powder flowability (higher FFC), and all ITZ composites were characterized as easy flowing (Schulze, 2008) .The angle of repose of composites is in the range 37−42°, which alsosuggestsgood flow properties. Along with these favorable flow properties, the bulk density of composites was in the range 0.49−0.65 g/cm 3 , which allows for direct compression of the composite powder for a tablet dosage form (Jallo et al., 2012) . Thus 370 the composites have excellent packing and compression properties.
The variations of polymer loading of the sprayed suspension (M1H−M6H) play an important role in the agglomeration behavior of the composite powders. As can be seen in Table 2 , an increase in the polymer loading in the composite due to increase of polymer concentration in the suspension, caused an increase in agglomeration ratio. A 375 higher polymer concentration in the drug suspension led to a higher viscosity which results in higher viscous dissipation of the kinetic energy of the colliding carrier particles and larger droplet sizes at the same atomization conditions (Bilgili et al., 2011; Chen et al., 2009b; Hemati et al., 2003) , and thus, to more pronounced agglomeration during the coating process. Although an increase of agglomeration ratiowas observed for high 380 polymer loading, the d 50 was still well under 100 μm for GranuLac ® 200 coated composites powders.It is also pointed out that the agglomeration ratiofollowed here (Chen et al., 2009b )is a rather strict measure of agglomeration, which accounts for the shift in the entire PSD in contrast to conventional size ratio enlargement measured in terms of particle d 50 .The median particle size of PrismaLac ® 40 increased from 321 µm to 380-385 385 µm due to coating and some low extent of agglomeration. spray-dried particles were observed in the SEM (Figs. 3d, h) . A closer view of the corresponding coated particle surfaces indicates the presence of drug nanoparticles (Figs.3e, g, i) .The lack of smoothness in core particles led to a non-homogenous coating of the suspensions with a variable thickness. The coating layerconsisting of drug nanoparticlesappears to surround the core GranuLac 
SEM images of dry-coated GranuLac
Drug Dissolution from NCMPs
The main motivation for producing nanoparticles of poorly watersolubledrugsis to improve their dissolution rate. Temporal evolution of drugs (ITZ, FNB) dissolved from 410 the NCMPs (coated on GranuLac where drug particles were embedded. During dispersion of the core-shell composite powder into thedissolution medium, a large amount of drug particles is wetted atthe same 420 time which can immediately start dissolving from the shell.
A comparison of the ITZ and FNB dissolution profiles obtained from discriminating test methods presented in Figs.4a and crespectively shows thatan increase in polymer loadingled to faster dissolution, which can beexplained by the smaller drug particle sizein the precursor milled suspensions (refer to Table 1) as well as faster and 425 more complete recovery of the drug nanoparticles during the dissolution. Moreover, when HPMC concentration was too low, hard aggregates might form during the drying process, causing slow and incomplete nanoparticle recovery during the dissolution.For FNB, there is no difference observed in dissolution profiles (see Fig.4b ) ofcomposites (F4−F6)that have different polymer concentration in their shells, which originatedfrom 430 the polymer concentration difference in the milled suspensions sprayed (M4H-M6H).This might be due to the dissolution media used (7.2 mg/ml SDS solution), which is well above the critical micellar concentration (CMC, 2.3 mg/ml) (Jamzad and Fassihi, 2006) .Such high SDS level led to very fast dissolving of FNB due to the micellar solubilization. Since FNB has very low aqueous solubility, such high concentration of 435 SDS is suggested in order to dissolve 48 mg of FNB. However, such high level of SDS does not allow for discriminating the impact of different HPMC levels in FNB composites (F4−F6) as compared with the redispersion testing. The dissolution profiles in Fig. 5c were obtained at a lower SDS concentration (2.88 mg/ml), albeit still slightly above the CMC value, which allowed for the discrimination of the faster dissolution at 440 higher polymer loading and revealed a trend similar to that observed for ITZ.It is noted that as the solubility was not significantly increased, the maximum dissolution achieved was 81%, but the dissolution profiles were discriminated sufficiently. A similar observation was made in other studies, e.g., as in Shah et al. (2016) , where dissolution of spray-dried griseofulvin powders was modulated by varying the non-sink conditions to 445 quantitatively discriminate the impact of various formulations, although maximum dissolution was below 60%.
To gain further insight into the impact of the polymer loading, separate redispersion tests were performed in which NCMPs were redispersed in the discriminating SDS media under stirring for 2 min and resulting particle size distributions 450 were measured. However, it is critical to note that redispersion tests with 30 mL SDS medium were designed to minimize drug dissolution within 2 min with the objective of measuring particle sizes, unlike the dissolution tests with 900 mL SDS medium. A comparison of the redispersed particle sizes (after 2 min) in Table 3 (Figs.4a and 4c ). As compared with previous investigations of the redispersion from drug nanocomposites prepared via fluidized bed coating (Bhakay et al., 2014a; Bhakay et al., 2013) , the redispersion from the nanocomposites in this study appears to be relatively poor, which 460 can be mainly explained by the extremely high drug loading (theoretical values of 85-95%) and low polymer:drug mass ratios in the shell of the nanocomposites. For example, the dried shell from 2.5% HPMC-0.2% SDS suspension had over 91% drug and hence high hydrophobicity of the drug appears to retard redispersion and consequently, dissolution. Moreover, when HPMC:drug mass ratio is low as in all these formulations, 465 hard aggregates might have formed during the drying process, causing slow and incomplete nanoparticle recovery during the redispersion/dissolution. Nonetheless, both the redispersion and dissolution tests show that higher HPMC level along with 0.2 % SDS provide faster drug release for both drugs. In summary, fast dissolving 60 µm or smaller freely flowing composites powders can be produced by fluid bed coating of wet-470 milled poorly water soluble drugs on nano-silica coated GranuLac respectively.Suspension M5H was chosen instead of M6H as there is no particle size difference observed between them (Table1). This also helps to minimize agglomeration 480 of NCMPs. The dissolution profiles obtained from USP-II dissolution apparatus for large composites L1 and L2 were compared with dissolution profiles forfine composites F3 and F5 (Fig.5a for ITZ and Fig.5b for FNB) . Based on the results from previous section shown in Figs.4b and 4c, lower level of SDS (discriminating medium) was used for FNB composites (Fig.5b) . As may be seen, the fine core-shell nanocomposite powder with 485 GranuLac ® 200 exhibited significantly faster drug dissolution than the composite powder with PrismaLac ® 40. Comparing the behavior of two drugs, it is apparent that the impact of the carrier size is more dominant in case of ITZ, which is significantly less soluble than FNB, for which a more discriminatory dissolution buffer was required for identifying the carrier size impact.A comparison of the redispersed particle sizes (after 2 490 min) in Table 3 for the formulations F3-L1 and F5-L2 also corroborate the dissolution results since L1 and L2 have much larger particles as compared to F3 and F5 respectively.
While d 50 of the redispersed L2 composites wasslightly lower than that of the redispersed F5 composites, the volume-mean diameter for L2 (17.8 m) was much higher than that for F5 (6.99 m), which also explains the observed dissolution behavior. These results 495 support the main hypothesis that smaller carrier owing to their higher surface area per unit mass and corresponding thinner drug-polymer shells, provide much faster drug release than the larger carrier with smaller surface area per unit mass and corresponding thicker drug-polymer shells.
Traditional USP II dissolution testing method is based solely on bulk solution 500 concentration measurements as a function of time. The lack of real-time information may preclude the possibility for understanding the behavior of a specific formulation.The UV imaging instrument is a novel emerging technique that can be used to visualizespatial variation of the drug solution concentration around a given solid sample in real time (Boetker et al., 2011; Østergaard et al., 2010; Qiao et al., 2013) . In this work,UV 505 imaging was utilized to gain further insights and find corroborating evidence for the impact of the carrier size. It is used for the qualitative assessment of differences in dissolution rates for large carrier and fine carrier coated composites. of dissolved drug and intrinsic dissolution rate (IDR),respectively.Intense color in absorbance map represents high dissolution of drug. The absorbance maps in Fig.6ashow that ITZ dissolved faster from F3 composite than fromL1 composite. The composite prepared with the fine carrier had higher cumulated amount of dissolved drug and IDR than both that prepared with the large carrier and the as-received drug (Figs.6b,c) .The 515 wide variation observed in Figs.6b,c seems to be a characteristic of the channel-flow cell set-up and the method, and has been observed by other researchers, albeit to different extent (Boetker et al., 2011; Gordon et al., 2013) . Østergaard et al.(2010) cautioned that this instrument is very sensitive to movements, vibrations, and residual flow and turbulence within the channel-flow cell. In addition, the drug content variability and 520 porosity variation of the compacted samples (n = 3) used in this study could have contributed to the wide variability observed here. Noting that we have only used the UV imaging for a qualitative assessment, results overall support the hypothesis that finer carriers can enhance drug release of very hydrophobic and poorly water soluble drugs.
Since the difference in the dissolution behavior may be largely attributed to 525 theshell film thickness, here it is estimated for both large and fine carriers. Given a mass of solid in the coating layer and a size of core particle, film thickness can be predicted based on mass balance and spherical particles assumption, as in Dewettinck and Huyghebaert (Dewettinck and Huyghebaert, 1998) . (Figs.7a andc) .
The coating layer thickness analysis and corresponding SEM imaging explain the slower dissolution rates for larger carriers due to thicker shell. The thicker shell also contributed to the poorer redispersion as evident from Table 3 . Overall, thinner shell 550 breaks down faster so that even highly hydrophobic ITZ nanoparticles get dispersed fairly rapidly. In contrast, thicker shell of larger carriers does not break down readily and redispersion PSD suggests presence of rather large chunks.The differences in their morphology were further assessed qualitatively via SEM imaging of the redispersed suspensions. Fig.8 shows SEM images of ITZ and FNB coated fine and large carrier 555 composites after redispersion. Clusters of nanoparticles as well as fragments of the coating shell and shrunken undissolved composites were found for L1 and L2 composites (see Figs.8c, g ). As GranuLac 
Summary and Conclusions
The impact of the size of the water-soluble carrier, i.e.,core particle, on dissolution behavior of poorly water-soluble drugs from their core-shell nanocompositemicroparticles was investigated. High drug loaded (30%) stable nanosuspensions of two BCS class II drugs, Itraconazole and Fenofibrate,were produced via wet media milling using 575 HPMC and SDS as stabilizers. It was found that while sufficient yet below CMC, 0.2 % SDS is critical for stability, higher HPMC loading led to finer milled drug particle sizes.Physical stability of drug suspension was also improved with the increase of HPMC loading. The nanosuspensions were then incorporated into a thin soluble shell of the core-shell nanocomposite powders via fluidized bed coating on fine dry-coated 580 properties that are suitable for sachet filling, capsule filling, and compression into tablets in pharmaceutical industry. Better nanoparticleredispersibility and dissolution were observed with the increase of HPMC loading for fine nanocomposites due to improved stabilization of the nanosuspensions and enhanced wettability of the shell. Moreover, thefine carrier particles offer a large surface area,which resulted in a thinnercoating layer 590 on carriersand subsequently faster dissolution and redispersion compared to thicker coating obtained due to large carriers.In-situ real-time dissolution imaging provided additional qualitative confirmation of improved dissolution. Overall, the hypothesis that greatly increased carrier surface area and corresponding thinner shell at the same drug loading formed using well-stabilized drug suspensionsfor finer carriers can significantly 595 increase the dissolution rate was proven. The results suggest that use of finer carriers may be useful for achieving immediate release from highly hydrophobic drugs such as Itraconazole. Tables   Table 1 Particle size of various drug suspensions after milling and after 7 days storage.
List of
Table 2
Properties of the nanocomposite (NCMPs) powders prepared with various milled suspensions via fluidized bed coating.
Table 3
Particle size statistics of the milled suspensions and redispersed NCMPs at 2 min. List of Figures   Fig. 1 . Process flow diagram (schematic) for the production of core-shell drug nanocomposite powders using fine/large carrier particles ( 
